IGVF Consortium Deciphering the impact of genomic variation on function , Nature, 633: 2024,47-57

Riggan KA, Feys R, Kokayi A, Meagher KM, Michie M, Musunuru K, Ormond KE, Schelhaas AJ, Yap JQ, Isasi R, Allyse MA. Grounded in reality: integrating community values and priorities of end users in human gene editing , Am J Bioeth, 24: 2024,43-45

Whittaker MN, Musunuru K. An epigenetic editor to silence genes , Science, 384: 2024,1407-1408

Lv W, Babu A, Morley MP, Musunuru K, Guerraty MA. Resource of gene expression data from a multiethnic population cohort of induced pluripotent stem cell-derived cardiomyocytes , Circ Genom Precis Med, 17: 2024,e004218

Brooks DL, Whittaker MN, Said H, Dwivedi G, Qu P, Musunuru K, Ahrens-Nicklas RC, Alameh MG, Wang X. A base editing strategy using mRNA-LNPs for in vivo correction of the most frequent phenylketonuria variant , HGG Adv, 5: 2024,100253

Brooks DL, Whittaker MN, Qu P, Musunuru K, Ahrens-Nicklas RC, Wang X. Efficient in vivo prime editing corrects the most frequent phenylketonuria variant, associated with high unmet medical need , Am J Hum Genet, 110: 2023,2003-2014

Musunuru K. Playing the genetic lottery: an interview with Kiran Musunuru , Dis Model Mech, 16: 2023,dmm050508

Whittaker MN, Testa LC, Quigley A, Jindal I, Cortez-Alvarado SV, Qu P, Yang Y, Alameh MG, Musunuru K, Wang X. Epigenome editing durability varies widely across cardiovascular disease target genes , Arterioscler Thromb Vasc Biol, 43: 2023,2075-2077

Allyse MA, Meagher KM, Michie M, Isasi R, Ormond KE, Bonhomme N, Bombard Y, Howard H, Musunuru K, Riggan KA, Rubeck S. Translational justice in human gene editing: bringing end user engagement and policy together , Am J Bioeth, 23: 2023,55-58

Testa LC, Musunuru K. Base editing and prime editing: potential therapeutic options for rare and common diseases , BioDrugs, 37: 2023,453-462